The presented invention comprises a theragnostic system that includes a carrier nanoparticle, a therapeutic agent of choice, an anti-FOLH1 monoclonal […]
The presented invention comprises a theragnostic system that includes a carrier nanoparticle, a therapeutic agent of choice, an anti-FOLH1 monoclonal […]